Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder

1. september 2026 opdateret af: PleoPharma, Inc.

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Clinical Trial of Titrating Doses of PP-01 for the Mitigation of Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder: Core Study With Safety Extension Phase

This study is a randomized, double-blind, placebo and active-controlled, multicenter trial conducted to evaluate whether PP-01 mitigates the withdrawal symptoms associated with discontinuing cannabis in participants with moderate to severe cannabis use disorder (CUD). Study participants will receive PP-01, nabilone, or placebo every day for 34 days. The total study duration will be approximately 78 days, including screening and a one-week inpatient stay. Following the initial inpatient portion of the study, participants will return to the clinic for six clinic visits and complete two telemedicine appointments. Participants will complete daily symptom diaries and other study-related questionnaires.

Participants who complete the core study may be eligible to participate in a repeat dosing extension study if they meet required criteria.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

420

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

  • Forenede Stater
    • Arkansas
      • Little Rock, Arkansas, Forenede Stater, 72211
        • Rekruttering
        • Woodland International Research Group, LLC
        • Ledende efterforsker:
          • George Konis, MD
      • Rogers, Arkansas, Forenede Stater, 72758
        • Rekruttering
        • Woodland Research Northwest, LLC
        • Ledende efterforsker:
          • Ryan Mahelona, MD
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06519
        • Rekruttering
        • Yale Stress Center
        • Ledende efterforsker:
          • Rajita Sinha, PhD
    • Florida
      • DeLand, Florida, Forenede Stater, 32720
        • Rekruttering
        • University Clinical Research-DeLand, LLC d/b/a Accel Research Sites - DeLand Clinical Research Unit
        • Ledende efterforsker:
          • Bruce G. Rankin, DO
      • Hollywood, Florida, Forenede Stater, 33024
        • Rekruttering
        • Research Centers of America
        • Ledende efterforsker:
          • Edwin A. Gomez, MD
      • Largo, Florida, Forenede Stater, 33777
        • Rekruttering
        • Sandhill Research, LLC d/b/a Accel Research Sites - St. Pete - Largo Clinical Research Unit
        • Ledende efterforsker:
          • Rosario B. Hidalgo, MD
      • Tampa, Florida, Forenede Stater, 33613
        • Rekruttering
        • ForCare Clinical Research
        • Ledende efterforsker:
          • Marlene P. Hart, MD
      • West Palm Beach, Florida, Forenede Stater, 33407
        • Rekruttering
        • Neuroscience Research Institute
        • Ledende efterforsker:
          • Danesh Alam, MD
    • Georgia
      • Decatur, Georgia, Forenede Stater, 30030
        • Rekruttering
        • Sandhill Research, LLC d/b/a Accel Research Sites - NeuroStudies Clinical Research Unit 755
        • Ledende efterforsker:
          • Marshall L. Nash, MD, FAHA, CPI, FAPCR
      • Norcross, Georgia, Forenede Stater, 30092
        • Rekruttering
        • Evergreen Clinical Trials
        • Ledende efterforsker:
          • Dmitriy Pelishev, DO
      • Savannah, Georgia, Forenede Stater, 31405
        • Rekruttering
        • CenExel iResearch, LLC
        • Ledende efterforsker:
          • Nancy E. Backus, MD
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40509
        • Rekruttering
        • AMR Clinical
        • Ledende efterforsker:
          • Peter Akpunonu, MD
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21228
        • Rekruttering
        • Maryland Psychiatric Research Center, University of Maryland School of Medicine
        • Ledende efterforsker:
          • David A Gorelick, MD, PhD
    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89121
        • Rekruttering
        • Oasis Clinical Research
        • Ledende efterforsker:
          • Stephen Tam, MD
    • New Jersey
      • Marlton, New Jersey, Forenede Stater, 08053
        • Rekruttering
        • Hassman Research Institute, LLC d/b/a CenExel Marlton, NJ
        • Ledende efterforsker:
          • Elan A. Cohen, PhD
    • New York
      • New York, New York, Forenede Stater, 10032
        • Rekruttering
        • The Research Foundation for Mental Hygiene/ New York State Psychiatric Institute
        • Ledende efterforsker:
          • John Mariani, MD
      • Staten Island, New York, Forenede Stater, 10314
        • Rekruttering
        • Richmond Behavioral Associates
        • Ledende efterforsker:
          • Romana Kulikova, MD
    • Ohio
      • North Canton, Ohio, Forenede Stater, 44720
        • Rekruttering
        • Neuro-Behavioral Clinical Research, Inc.
        • Ledende efterforsker:
          • Shishuka Malhotra, MD
    • South Carolina
      • North Charleston, South Carolina, Forenede Stater, 29405
        • Rekruttering
        • Coastal Carolina Research Center, LLC
        • Ledende efterforsker:
          • Elizabeth Perkins, MD
    • Tennessee
      • Knoxville, Tennessee, Forenede Stater, 37920
        • Rekruttering
        • AMR Clinical
        • Ledende efterforsker:
          • Jerry L. Punch, MD
    • Texas
      • Austin, Texas, Forenede Stater, 78754
        • Rekruttering
        • Community Clinical Research, Inc.
        • Ledende efterforsker:
          • David Brown, MD
      • Houston, Texas, Forenede Stater, 77043
        • Rekruttering
        • Memorial Hermann Village
        • Ledende efterforsker:
          • Dominick Stevan D'Aunno, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  1. Generally healthy adults between the ages of 18 and 55, inclusive.
  2. Meet DSM-5 diagnostic criteria for current moderate to severe CUD as confirmed by a licensed physician or psychologist or addiction medicine specialist.
  3. BMI within 18.0 to 38.0 kg/m2, inclusive.
  4. Female participants must not be pregnant or lactating. If of childbearing potential - the participant agrees to use an accepted contraceptive regimen.
  5. Male participants who are fertile and engage in sexual activity must agree to use a double barrier method (e.g., condom and spermicide) during the study and to not donate sperm for 90 days after the last dose of study medication.
  6. Be seeking and motivated to discontinue cannabis and to minimize withdrawal symptoms.
  7. Agree to not use cannabis or any product containing CBD, hemp derivatives, terpenes or any THC containing product including delta-8, delta-10, THC-A or any other cannabinoid-like product following Randomization and throughout the study duration.
  8. Meet DSM-5 Cannabis Withdrawal Criteria.
  9. Report heavy use of daily/near daily cannabis.
  10. Have a urine drug screen positive for THC/THC metabolite and have a negative result for all other illicit/excluded drugs and alcohol at Screening and Randomization.
  11. Capable of giving informed consent and stated willingness to comply with all study procedures including inpatient and weekly outpatient visits, daily evening video calls, restrictions, and availability for the duration of the study.
  12. Willing to be admitted to an inpatient clinic with overnight stays on Days 1 through 6 and return for all outpatient visits.
  13. Ability to take study drug capsules at approximately the same time each day.
  14. Have regular access to the internet and access to video/virtual capabilities for video calls by any means.
  15. Agree to not use any alcohol during the study.
  16. No plan to change current nicotine use.
  17. Ability to read, understand, and complete daily diaries.

Exclusion Criteria:

  1. Lifetime history of DSM-5 diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder.
  2. Current DSM-5 criteria for a psychiatric disorder that in the Investigator's judgment is unstable, would be disrupted by the study medication, or is likely to require new pharmacotherapy or psychotherapy during the study period. Individuals who are currently stable on psychotropic medication for at least 3 months may be included at the discretion of the Investigator's judgement.
  3. Participants who meet DSM-5 criteria for any history of or current drug use disorder within the previous 2 years, other than cannabis, nicotine, or caffeine use disorders.
  4. Participants who consume alcohol on a regular or frequent basis and who do not agree or are deemed by the Investigator to be unable to discontinue alcohol for the duration of the study.
  5. Participants using cannabis for a physician directed medical condition requiring use such as epilepsy.
  6. Any clinically important abnormalities on Screening physical examination, assessments, electrocardiogram, or laboratory tests.
  7. Current or recent history of significant violent or suicidal behavior, risk for suicide or homicide.
  8. History of clinically significant medical condition that, in the opinion of the Principal Investigator, would jeopardize the safety of the participant or impact on the validity of the study results.
  9. Participants with risk factors for seizure.
  10. Known history of allergy, intolerance, or hypersensitivity to nabilone, gabapentin, or pregabalin.

  11. Prohibited medications at Screening:

    • Current use of narcotics, psychedelics, stimulants, opioid agonists and antagonists, kratom, illicit drugs, ketamine, unregulated psychoactive drugs (sometimes known as "gas station drugs"), or products intended to induce a feeling of being high except for cannabis
    • Regular benzodiazepine use (more than once per week) and no use within 7 days of Baseline Visit (Day 1)
    • Current use (within 7 days of Baseline Visit) of OTC products to help with sleep or anxiety
    • Prescription medications to help with sleep or anxiety within 14 days of Screening
    • Current use of nabilone, dronabinol, Sativex, Epidiolex, synthetic cannabinoids
    • Gabapentin or pregabalin or use within 30 days of Screening
  12. Heavy users of alcohol within 60 days of Screening or binge drinkers of alcohol within 30 days of Screening.
  13. A positive urine drug/alcohol test at Screening or Randomization for narcotics and/or illicit drugs other than cannabis. If the test is positive for benzodiazepines or alcohol at Screening, and if it is reported that they are only occasional users, a repeat urine drug screen can be performed at the discretion of the Medical Monitor and must be negative at the time of Randomization.
  14. Use of an investigational drug or biologic within 30 days or 5 times the half-life (whichever is longer) prior to the Screening Visit.
  15. Active influenza or COVID-19 infection or planned vaccination.
  16. Prior participation in any PleoPharma clinical study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: PP-01
Oral PP-01 tapered/titrated over 34 days
Kombinationsprodukt: PP-01
Cannabinoid-1 (CB1) partial agonist / GABAergic modulator
Aktiv komparator: Nabilone
Oral Nabilone tapered/titrated over 34 days
Medicin: Nabilone
CB1 partial agonist
Placebo komparator: Placebo
Oral Placebo given daily for 34 days
Medicin: Placebo
Placebo komparator

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
AUCs of the CSCW over Days 2 to 7, inclusive, comparing PP-01 vs Placebo
Tidsramme: Days to 2 to 7
Days to 2 to 7
AUCs of the CSCW over Days 25 to 35, inclusive, comparing PP-01 vs Nabilone to assess rebound
Tidsramme: Days 25 to 35
Days 25 to 35

Sekundære resultatmål

Resultatmål
Tidsramme
AUCs of CWS-20 Irritability Domain scores over Days 2 to 35 comparing PP-01 vs Placebo
Tidsramme: Days 2 to 35
Days 2 to 35
AUCs of CWS-20 Irritability Domain scores over Days 25 to 35 comparing PP-01 vs Nabilone
Tidsramme: Days 25 to 35
Days 25 to 35
AUCs of the CSCW over Days 2 to 35 comparing PP-01 vs Placebo
Tidsramme: Days 2 to 35
Days 2 to 35
AUCs of CWS-20 Sleep Domain scores over Days 2 to 35 comparing PP-01 vs Placebo
Tidsramme: Days 2 to 35
Days 2 to 35
AUCs of CWS-20 Sleep Domain scores over Days 2 to 7 comparing PP-01 vs Placebo
Tidsramme: Days 2 to 7
Days 2 to 7
AUCs of CWS-20 Craving Domain scores over Days 2 to 35 comparing PP-01 vs Placebo
Tidsramme: Days 2 to 35
Days 2 to 35
AUCs of CWS-20 Craving Domain scores over Days 2 to 7 comparing PP-01 vs Placebo
Tidsramme: Days 2 to 7
Days 2 to 7

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

PleoPharma, Inc.

Efterforskere

  • Studieleder: Jay Constantine, MD, PleoPharma, Inc.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

17. juni 2026

Primær færdiggørelse (Anslået)

1. juni 2027

Studieafslutning (Anslået)

1. september 2027

Datoer for studieregistrering

Først indsendt

8. juni 2026

Først indsendt, der opfyldte QC-kriterier

8. juni 2026

Først opslået (Faktiske)

12. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

2. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • CAN-004

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner